{"id":"W2020299781","doi":"10.1007/s00280-011-1671-3","title":"PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma","year":2011,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Aldose Reductase and Taurine","field":"Biochemistry, Genetics and Molecular Biology","cited_by":36,"is_retracted":false,"has_abstract":false,"ca_institutions":"Impact","funders":"","keywords":"Sorafenib; Hepatocellular carcinoma; Medicine; Neutropenia; Internal medicine; Gastroenterology; Discontinuation; Liver function; Cohort; Pharmacokinetics; Pharmacology; Oncology; Toxicity","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005779576,0.0005707518,0.002026519,0.0002969441,0.0002996858,0.0004978478,0.0002513317,0.0003980207,0.00134408],"category_scores_gemma":[0.001044165,0.0002686967,0.001121003,0.000483698,0.0002616601,0.0006676306,0.0002635912,0.001207578,0.00022843],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005018801,"about_ca_system_score_gemma":0.0006761199,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009629636,"about_ca_topic_score_gemma":0.002595923,"domain_scores_codex":[0.999733,0.0001144435,0.00003076768,0.00003211144,0.00002833227,0.0000613177],"domain_scores_gemma":[0.9996454,0.00009039891,0.00006724555,0.00001795872,0.00002122655,0.0001578154],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4886832,0.005303773,0.1466508,0.001572888,0.003241032,0.003002882,0.0004098846,0.004032022,0.01939013,0.000413416,0.003464634,0.3238353],"study_design_scores_gemma":[0.1147435,0.2560726,0.5892162,0.0002775402,0.006321787,0.005783516,0.0007995273,0.007022059,0.005708741,0.001293256,0.01258897,0.0001723178],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9922016,0.005359356,0.0001806558,0.0004808134,0.0001254351,0.00008137517,0.0001434138,0.00003467924,0.001392712],"genre_scores_gemma":[0.9974871,0.001384839,0.0001859595,0.0001809031,0.0000829383,0.0000387001,0.0002193711,0.000003913663,0.0004163407],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002026519,"threshold_uncertainty_score":0.004496396,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01115251387590443,"score_gpt":0.2449526521845511,"score_spread":0.2338001383086467,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}